Objective: To assess the management of symptomatic leiomyomas using a nonsteroidal aromatase inhibitor in perimenopausal women.
Design: Case report.
Setting: Academic clinical practice.
Patient(s): A 53-year-old woman suffering from recurrent urinary retention secondary to a uterine leiomyoma.
Intervention(s): Fadrozole, orally, 2 mg daily for 8 weeks and then 1 mg daily for 4 weeks.
Main outcome measure(s): Measurements of leiomyoma volume, and levels of serum E(2), LH, and FSH.
Result(s): Urinary retention resolved after 2 weeks of treatment and did not recur. Leiomyoma volume estimated by ultrasonography revealed a 71% reduction after 8 weeks of treatment.
Conclusion(s): Fadrozole was useful for the management of a symptomatic leiomyoma without transient deterioration of symptoms. Clinical trials are warranted.